Jazz Pharmaceuticals (JAZZ) Debt to Equity (2010 - 2026)

Jazz Pharmaceuticals' Debt to Equity history runs 17 years deep, the most recent figure standing at $1.18 for Q1 2026.

• In Q1 2026, Debt to Equity fell 8.11% year-over-year to $1.18; the TTM figure through Mar 2026 stood at $1.18 (down 8.11% YoY), while the FY2025 annual figure was $1.24, down 16.85% from the prior year.
• Debt to Equity was $1.18 for Q1 2026 at Jazz Pharmaceuticals, down from $1.24 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $2.09 in Q3 2022 to a low of $1.18 in Q1 2026.
• Historically, Debt to Equity has averaged $1.56 across 5 years, with a median of $1.53 in 2023.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity surged 201.65% in 2022, then decreased 21.49% in 2023.
• A 5-year view of Debt to Equity shows it stood at $1.86 in 2022, then decreased by 17.59% to $1.53 in 2023, then declined by 2.39% to $1.49 in 2024, then declined by 16.85% to $1.24 in 2025, then slipped by 4.78% to $1.18 in 2026.
• The last three Debt to Equity figures came in at $1.18 (Q1 2026), $1.24 (Q4 2025), and $1.35 (Q3 2025), per Business Quant data.